Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT
Standard
Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT. / Sanz, Jaime; Labopin, Myriam; Blaise, Didier; Raiola, Anna Maria; Busca, Alessandro; Vydra, Jan; Tischer, Johanna; Chevallier, Patrice; Bramanti, Stefania; Fanin, Renato; Socié, Gerard; Forcade, Edouard; Kröger, Nicolaus; Koc, Yener; Itälä-Remes, Maija; Zecca, Marco; Nagler, Arnon; Brissot, Eolia; Spyridonidis, Alexandros; Bazarbachi, Ali; Giebel, Sebastian; Piemontese, Simona; Mohty, Mohamad; Ciceri, Fabio.
In: BLOOD ADV, Vol. 8, No. 10, 28.05.2024, p. 2332-2341.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT
AU - Sanz, Jaime
AU - Labopin, Myriam
AU - Blaise, Didier
AU - Raiola, Anna Maria
AU - Busca, Alessandro
AU - Vydra, Jan
AU - Tischer, Johanna
AU - Chevallier, Patrice
AU - Bramanti, Stefania
AU - Fanin, Renato
AU - Socié, Gerard
AU - Forcade, Edouard
AU - Kröger, Nicolaus
AU - Koc, Yener
AU - Itälä-Remes, Maija
AU - Zecca, Marco
AU - Nagler, Arnon
AU - Brissot, Eolia
AU - Spyridonidis, Alexandros
AU - Bazarbachi, Ali
AU - Giebel, Sebastian
AU - Piemontese, Simona
AU - Mohty, Mohamad
AU - Ciceri, Fabio
N1 - Copyright © 2024 American Society of Hematology.
PY - 2024/5/28
Y1 - 2024/5/28
N2 - There is a paucity of information to guide the selection of the most suitable donor in haploidentical (Haplo) hematopoietic stem cell transplantation (HSCT). For this reason, from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we conducted a retrospective analysis to evaluate the impact of Haplo donor characteristics on outcomes in patients with acute myeloid leukemia (AML) who received graft-versus-host disease prophylaxis with posttransplant cyclophosphamide (PTCy). The primary end point was graft-versus-host disease (GVHD)-free and relapse-free survival (GRFS). Overall, 2200 patients were included. The median age of donors was 37 years (range, 8-71); 820 (37%) were females, including 458 (21%) who were used for male recipients. In addition, 1631 donors (74%) donated peripheral blood (PB). Multivariable analysis identified certain donor-related risk factors with a detrimental impact on transplant outcomes. The use of PB, older donors' ages (>37 years), and female donors to male recipients negatively affected GRFS. Donor's age and female donor-to-male recipient combination also affected nonrelapse mortality, leukemia-free survival, and overall survival. In conclusion, donor-related variables significantly influence outcomes in patients with AML after Haplo-HSCT with PTCy. When possible, younger donors and male donors for male recipients should be prioritized. The use of bone marrow can additionally prevent GVHD.
AB - There is a paucity of information to guide the selection of the most suitable donor in haploidentical (Haplo) hematopoietic stem cell transplantation (HSCT). For this reason, from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we conducted a retrospective analysis to evaluate the impact of Haplo donor characteristics on outcomes in patients with acute myeloid leukemia (AML) who received graft-versus-host disease prophylaxis with posttransplant cyclophosphamide (PTCy). The primary end point was graft-versus-host disease (GVHD)-free and relapse-free survival (GRFS). Overall, 2200 patients were included. The median age of donors was 37 years (range, 8-71); 820 (37%) were females, including 458 (21%) who were used for male recipients. In addition, 1631 donors (74%) donated peripheral blood (PB). Multivariable analysis identified certain donor-related risk factors with a detrimental impact on transplant outcomes. The use of PB, older donors' ages (>37 years), and female donors to male recipients negatively affected GRFS. Donor's age and female donor-to-male recipient combination also affected nonrelapse mortality, leukemia-free survival, and overall survival. In conclusion, donor-related variables significantly influence outcomes in patients with AML after Haplo-HSCT with PTCy. When possible, younger donors and male donors for male recipients should be prioritized. The use of bone marrow can additionally prevent GVHD.
U2 - 10.1182/bloodadvances.2023012133
DO - 10.1182/bloodadvances.2023012133
M3 - SCORING: Journal article
C2 - 38429091
VL - 8
SP - 2332
EP - 2341
JO - BLOOD ADV
JF - BLOOD ADV
SN - 2473-9529
IS - 10
ER -